In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Richard T. Williams, MD, PhD
Assistant Member, St. Jude Faculty
Departments
Oncology
Divisions
Molecular Therapeutics
Contact Information
Richard Williams, MD, PhD
Molecular Therapeutics
MS 310, Room D5062C
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: richard.williams@stjude.org
Phone: (901) 595-4215
FAX: (901) 595-5939
Education
BMedSci - University of Queensland, Brisbane, Australia
MBBS - University of Queensland, Brisbane, Australia
PhD - University of Queensland, Brisbane, Australia
Research Interests
- Function of the CDKN2A (ARF/p16INK4A) tumor suppressor locus in leukemias.
- Biology, genetics and therapeutics of BCR-ABL-induced lymphoid leukemias.
Selected Publications
Williams RT, Sherr CJ. BCR-ABL and CDKN2A: a dropped connection (letter to the editor). Nature Rev. Cancer 8, 563, 2008.
Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev 22(11):1411-1415, 2008.
Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL(+), Arf-null lymphoblastic leukemia. Genes Dev 21(18):2283-2287, 2007.
Williams RT, Sherr CJ. The Arf Tumor Suppressor in Acute Leukemias: Insights from Mouse Models of Bcr-Abl-Induced Acute Lymphoblastic Leukemia.: In: d'Adda di Fagagna, F.; Chiocca, S.; McBlane, F.; Cavallaro, U. (Eds.) Advances in Molecular Oncology: Advances in Experimental Medicine and Biology Oncology (Vol 604): Proceedings of the 2nd IFOM-IEO Meeting on Cancer 2006, May 5-8; Milan, Italy. Berlin: Springer; 2007. p107-114.
Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA April 25; 103(17): 6688-93, 2006.
den Besten W, Kuo M-L, Tago K, Williams RT, Sherr CJ. Ubiquitination of, and Sumoylation by, the Arf tumor Suppressor. Israel Medical Assoc Journal 8: 249-251, 2006.
den Besten W, Kuo M-L, Williams RT, Sherr CJ. Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53-Dependent and Independent Activities of the Arf Tumor Suppressor Protein. Cell Cycle 4 (11): 1593-98, 2005.
Sherr CJ, Bertwistle D, den Besten W, Kuo M-L, Sugimoto M, Tago K, Williams RT, Zindy F, Roussel, MF. p53-Dependent and -Independent functions of the Arf Tumor Suppressor. Cold Spring Harbor Symposium on Quantitative Biology: Molecular Approaches to Controlling Cancer Vol 70, 129-137, 2005.
Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA Dec 23;100(26):15930-5, 2003.
Last update: June 2008
